California Medicaid spending on GLP-1 drugs

How much did California Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $3.46 billion for GLP-1 drugs paid through California Medicaid in 2025, across at least 3,090,452 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 50 rows of 319, so these figures are floors.

Pharmacies were reimbursed at least $537.7 million for GLP-1 drugs paid through California Medicaid in 2026 (quarter 1 only, as posted so far), across at least 498,619 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 16 rows of 86, so these figures are floors.

By year and ingredient

2020at least $54,589,020No data$38,337,979at least $77,900,795at least $20,395,327$319,279$1,258,475$660,709at least $193,461,582
2021at least $102,170,482No data$40,178,351at least $143,919,369at least $13,566,430$869,840$1,722,060$519,605at least $302,946,136
2022at least $270,073,314at least $6,370,537at least $69,114,221at least $224,469,699at least $9,171,144at least $263,680at least $1,990,662at least $739,304at least $582,192,561
2023at least $867,000,433at least $59,286,722at least $98,240,395at least $281,352,773at least $6,431,429at least $9,649at least $1,764,021at least $799,957at least $1,314,885,379
2024at least $1,743,503,676at least $237,439,352at least $36,973,749at least $195,689,376$3,445,687No dataat least $1,300,036at least $561,560at least $2,218,913,436
2025at least $2,325,087,297at least $991,748,713at least $19,837,924at least $124,091,865at least $715,958No dataat least $785,527at least $276,693at least $3,462,543,976
2026 (Q1)at least $318,166,487$192,263,663at least $2,435,862at least $24,620,972$8,837No dataat least $119,418at least $66,186at least $537,681,425

By product, 2025

Ozempicat least $888,872,945at least 915,0842 of 39
Rybelsus$123,413,85685,5050 of 24
Wegovy$1,312,800,4961,000,3040 of 40
Mounjaro$247,591,112233,5350 of 48
Zepboundat least $744,157,601at least 701,82712 of 46
Liraglutide (generic name listing)at least $4,137,026at least 9,71016 of 41
Saxendaat least $13,231,788at least 10,8684 of 8
Victoza$2,469,1103,8620 of 8
Trulicityat least $124,091,865at least 127,7744 of 37
Bydureonat least $680,485at least 8161 of 5
Byettaat least $27,308at least 312 of 4
Exenatide (generic name listing)at least $8,165at least 112 of 3
Soliquaat least $785,527at least 9163 of 8
Xultophyat least $276,693at least 2094 of 8

By quarter, 2025

Q1 2025at least $707,284,214at least 633,55910 of 77
Q2 2025at least $692,654,946at least 617,91417 of 81
Q3 2025at least $1,072,848,849at least 955,91710 of 79
Q4 2025at least $989,755,968at least 883,06213 of 82

By quarter, 2026 (posted so far)

Q1 2026at least $537,681,425at least 498,61916 of 86

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.